Financial Data and Key Metrics Changes - TG Therapeutics reported approximately $616 million in total global revenue for 2025, with $594 million coming from U.S. net sales of BRIUMVI, marking a 92% year-over-year growth and a 20% sequential growth from Q4 over Q3 [5][20] - The company achieved an operating income of $123 million for the year, with a net income of $447.2 million, or $2.77 per diluted share, compared to $23.4 million, or $0.15 per diluted share in 2024 [22][25] Business Line Data and Key Metrics Changes - BRIUMVI U.S. net revenue reached $594 million for the full year, with Q4 net sales of $183 million, reflecting sustained momentum and growth driven by new patient starts and prescriber expansion [12][20] - Breyanzi continues to strengthen its position in the anti-CD20 market, with a balanced mix of treatment-naive and switch patients contributing to its growth [13] Market Data and Key Metrics Changes - The company expects full-year U.S. Breyanzi net revenue guidance of $825 million-$850 million for 2026, with total global revenue projected at $875 million-$900 million [16] - The first quarter of 2026 is expected to see U.S. revenue grow sequentially to approximately $185 million-$190 million, despite typical seasonal headwinds [17] Company Strategy and Development Direction - TG Therapeutics aims to maximize the multi-billion dollar BRIUMVI opportunity while expanding its pipeline judiciously for sustained future growth [9] - The company is developing a self-administered subcutaneous BRIUMVI, targeting pivotal top-line data later this year or early next year, with a potential 2028 launch [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in generating positive cash flow in 2026 and beyond, highlighting the company's financial flexibility within the biotech sector [9] - The management team emphasized the importance of building a strong presence in the MS community and supporting patients beyond just commercializing BRIUMVI [11] Other Important Information - The company completed its first $100 million share repurchase program and authorized an additional $100 million, indicating confidence in its long-term outlook [23] - The partnership with Christina Applegate for the Next in MS initiative aims to provide resources and support for individuals living with MS [10] Q&A Session Summary Question: Dynamics of sub-Q uptake in community practices - Management noted that they continue to gain share in the IV segment and are not seeing decreases in switches from Ocrevus to BRIUMVI, with strong momentum across both private practice and academic centers [27][29] Question: Proportion of new versus switch patients - Management confirmed record new patient enrollments and strong persistence among existing patients, contributing to continued growth [35][38] Question: Incremental investments for sub-Q launch - Management indicated that the overlap between the current field force for IV and sub-Q is about 80%, suggesting minimal incremental costs for the sub-Q launch [42][47] Question: Market perspective on ENHANCE trial - Management believes that eliminating the second dose will enhance convenience for patients and could lead to market share gains [70][71] Question: Early metrics from DTC launch and Next in MS program - Engagement metrics from the Next in MS initiative have exceeded expectations, with positive feedback from customers and advocacy groups [75]

Core Insights - TG Therapeutics reported total revenue of $141.1 million for Q2 2025, with BRIUMVI U.S. net revenue at $138.8 million, reflecting a 91% increase year-over-year and a 16% increase from Q1 2025 [1][5][36] - The company raised its full-year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million, up from a previous guidance of $560 million [1][5] - TG Therapeutics is focused on the commercialization of BRIUMVI, which is gaining traction as a leading anti-CD20 therapy for relapsing multiple sclerosis (MS) [2][5] Financial Performance - BRIUMVI U.S. net product revenue for Q2 2025 was $138.8 million, marking a 91% growth compared to Q2 2024 and a 16% increase over Q1 2025 [5][36] - Total revenue for the first half of 2025 reached $262 million, compared to $136.9 million in the same period of 2024 [36] - The company reported a net income of $28.2 million for Q2 2025, compared to a net income of $6.9 million in Q2 2024 [11][36] Pipeline and Development - TG Therapeutics is advancing its pipeline with ongoing clinical trials, including a Phase 3 trial for a consolidated Day 1 and Day 15 dosing regimen for IV BRIUMVI [5][11] - The company has commenced patient enrollment for a Phase 1 clinical trial evaluating azer-cel for autoimmune diseases [5][11] - BRIUMVI has been approved for commercialization in the European Union, United Kingdom, Switzerland, and Australia, expanding its market reach [5][11] Market Position and Strategy - The company emphasizes the strong uptake of BRIUMVI, supported by physician confidence and positive patient experiences, which are critical to its launch strategy [2][5] - Innovations such as a subcutaneous formulation and combined dosing regimens are being studied to enhance BRIUMVI's market position [2][5] - TG Therapeutics aims to redefine treatment expectations for patients with MS through its strategic initiatives and product offerings [2][5]